drugset / Trial / NCT00576563

Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer

NCT00576563 ↗

Completed 103 enrolled Maastricht Radiation Oncology
NaSingle-groupOpen-labelTreatment

Summary

To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy. The changes of the FDG uptake of the primary tumour and the evolution of key tumour characteristics during radiotherapy alone or in combination with chemotherapy will be predictive for the pathological tumour response. Study hypothesis The changes of the FDG uptake of the primary tumour and the evolution of key tumour characteristics during radiotherapy alone or in combination with chemotherapy will be predictive for the pathological tumour response.

Timeline

Start
2007-03
Primary completion
2015-01
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-deoxyglucose Diagnostic / imaging agent — Intravenous

Indications